SI-BONE is a fast-growing, publicly traded medical device company that is an industry pioneer in minimally invasive sacropelvic solutions. Our mission is to help patients rise up and reach for the stars, and our vision is to work together as the global leader to make sacropelvic conditions universally recognized and effectively treated through innovation, evidence, education, and advocacy.

Territory Representative

Territory: Philadelphia

Salary: $60,000-80,000 plus monthly variable pay, based on quarterly MBO performance

General Responsibilities:

Reports to the hiring Regional Sales Director and has responsibility for managing specified territory as determined by senior management.
Provide leadership and performance to ensure that company goals are achieved.
Responsible for identifying, targeting, and training of surgeons for the purpose of performing iFuse cases.
Responsible for marketing to all clinician groups within the patient referral network to create awareness and support educational activities around SI joint diagnosis and treatment to maximize the flow of patients to local trained iFuse surgeons.
Responsible for meeting goals and sales quotas as communicated by the Territory Manager and Sales Management.
Responsible for individually and independently providing technical assistance and covering cases in the operating room as needed on a regional basis.
The Territory Associate Representative must at all times act and conduct company business in an honest, ethical and strictly legal manner, complying with the Code of Conduct, other company policies, the AdvaMed Code and all applicable laws and regulations, whether national, regional, state or local. This individual is encouraged, expected, and required to report any suspected violations of laws, regulations, the Code or any other Company policy, and all other suspected unethical behavior. The company does not tolerate retaliation in connection with making good faith reports of suspected violations.

Specific Responsibilities:

Establish rapport and a solid working relationship with surgeon customers as well as with all employees.
Assist Territory Manager and Region in meeting or exceeding quota on a consistent basis.
Manage all travel and entertainment expenses consistent with company policy and within regional budget guidelines.
Establish and manage referral channel networks; utilize integrated marketing information, high prescriber lists, and other leads to identify physicians and patients interested in SI joint treatment options.
Work closely with sales management to identify, execute and support educational activities within the territory to ensure maximum awareness of the SI joint as a pain generator and establish solid referral patterns to trained iFuse surgeons.
Provide the necessary reporting materials and communicate effectively and openly to the Territory Manager and Sales Management Team as required.
Responsible for management of implant shelf life and instrument sets provided to them. Damaged or expired product to be returned to SI-BONE, Inc.
Support the SI-Bone Quality System.

Expertise:

Currently or recently served in a sales position of a high-growth, medical device or pharmaceutical organization whose products are marketed to a medical specialty practice and worked in a leadership capacity for a minimum of 3 years.
Experience in orthopedics or pain management is desired. Spine experience also a plus.
Strong relationships with local physician groups, including primary care, pain management, orthopedic and neurosurgery.
A demonstrated ability to communicate effectively and work well with sales management.
Results oriented and customer focused.
Demonstrated adaptability and initiative.
A demonstrated history of successfully achieving goals, objectives and high performance.
A positive, self-confident and decisive work ethic with excellent communication skills in both oral and written formats, as well as excellent listening skills.
A proactive approach to attacking problems and identifying solutions, displaying initiative and perseverance in order to bring about meaningful change and is open and responsive to new ideas.
Be known as a person who has high integrity, sound character, a tremendous work ethic and the passion to succeed.
Knowledge and familiarity of applicable regulations/standards (e.g. ISO 13485, FDA 21 CFR 820, EU MDR 2017/745, ISO 14971) as required to perform the job function

Education and Experience:

Bachelor’s Degree in Marketing, Finance, Business or equivalent discipline.

Salary range: The compensation range for this position is specific to the location and is in good faith what SI-BONE expects to pay for the position taking into account the wide variety of factors that are considered in making compensation decisions, including job-related knowledge; skillset; experience, education and training; certifications; and other relevant business and organizational factors.

Supplemental pay: stock

There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For additional information on the company or the products including risks and benefits, please visit www.si-bone.com/risks.

We are aware of active recruitment scams using the SI-BONE name, in which individuals pose as our recruiters and post fake remote job openings and make fake job offers on the Internet. Please note, we will never make an offer of employment without conducting multiple rounds of interviews face-to-face using secure video-conferencing technology. We will never ask candidates to cash checks or make a payment in order to be considered for a position. SI-BONE only uses company email addresses, which contain “@si-bone.com” to communicate with candidates.

If you believe you’ve been a victim of a phishing scam, please visit the Cybersecurity & Infrastructure Security Agency at https://www.cisa.gov/be-cyber-smart/report-incident learn how to report it.

About the company

SI-BONE focuses on treating sacroiliac joint dysfunction, a common source of lower back pain, by offering a minimally invasive implant system called iFuse. The iFuse Implant System is implanted surgically to stabilize the sacroiliac joint with a less invasive approach that aims for quicker recovery compared to traditional methods. The company gained FDA clearance for this implant, validating its use in patients. In 2018, SI-BONE went public on the NASDAQ, providing capital to expand research, development, and market presence. Its ongoing goal is to improve patient outcomes through education and continued development of sacroiliac joint treatments. Unlike broader orthopedic device makers, SI-BONE specializes in a targeted SI joint solution and builds its business around a single reusable implant technology and related surgical tools.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Jose, California

Founded

2008

Get referred to SI-BONE

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue reached $56.0 million, up 15.2%, with positive adjusted EBITDA.
Cash from operations turned positive in Q2 2026, ending June with $145.9 million.
International revenue rose 25.9%, while Onyx opens a new compromised-bone market.

What critics are saying

October 2025 breach investigations expose SI-BONE to class actions and regulatory penalties.
Medtronic and Globus dominate spine sales, squeezing SI-BONE’s distribution and pricing power.
If reimbursement momentum fades, SI-BONE’s growth story collapses before sustained GAAP profitability.

What makes SI-BONE unique

iFuse Granite Onyx cleared September 28, 2026, expanding beyond pelvic fixation.
SI-BONE grew active U.S. physicians 19% to 1,715 by Q2 2026.
CMS raised payments October 1, 2026 for iFuse Bedrock Granite spinal fusions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Associated Press

Sep 28th, 2026

SI-BONE wins FDA clearance for iFuse Granite Onyx to tackle spinal fusion loosening in compromised bone

SI-BONE has received FDA 510(k) clearance for its iFuse Granite Onyx System, the company's first product for compromised bone intended for use outside the pelvis. The system addresses screw loosening at the upper and lower instrumented vertebrae of spinal fusion constructs, which occurs in up to 27% of cases. The technology features a bone-density-specific surface and anatomy-specific thread form designed for rapid osseointegration and reduced micromotion. It targets patients with low bone density, who face elevated loosening risk and higher revision rates. Onyx is SI-BONE's third platform designated as a breakthrough device. The clearance expands the company's market opportunity beyond its existing pelvic applications. Since 2009, SI-BONE has supported physicians in performing over 150,000 procedures.

GlobeNewswire

Sep 8th, 2026

Carlsmed, Inc. announces Chief Operating Officer appointment.

Carlsmed, Inc. announces Chief Operating Officer appointment. September 08, 2026 16:05 ET | Source: Carlsmed CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) - Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the Company's Senior Vice President, Operational Excellence and previously, Vice President of Advanced Manufacturing Technologies. Prior to joining Carlsmed, Jeff held senior leadership positions in operations and technology at SI-BONE, NuVasive, and US Surgical. "Jeff has made measurable contributions to our operations, driving deployment of advanced technologies throughout our digital production process to accelerate scale and capabilities," said Mike Cordonnier, Chairman and CEO. "We look forward to his leadership to further expand our capabilities to rapidly scale our highly differentiated personalized surgery business." Mr. Bertolini holds an MBA from Rensselaer Polytechnic Institute and a Bachelor of Science in Procurement and Logistics Management from Arizona State University. He completed the Chief Technology Officer Program at the Wharton School of the University of Pennsylvania and the MIT Professional Education Program in Applied Data Science. About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. Forward Looking Statements Any statements in this press release about future expectations, plans and prospects, including statements about Carlsmed's ability to scale its business and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "likely," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption "Risk Factors" in Carlsmed's Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed's views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed's views as of any date subsequent to the date of this press release.

BioPharma Watch

Aug 31st, 2026

SI-BONE to present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026.

SI-BONE to present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026. Key Takeaway: SI-BONE, Inc. will participate in the 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York. The company will host a fireside chat on September 14, 2026, at 8:30 a.m. PT. Investors can register to listen live or access the archived webcast on the company's website. Market sentiment analysis. Positive factors. * SI-BONE is recognized as a global leader in procedural solutions. * The company has a strong track record with over 150,000 procedures performed. * Management's participation in a major healthcare conference highlights its visibility. SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) - SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24 th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: SI-BONE, Inc. - 1774169. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event. About SI-BONE, Inc. SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 190 peer reviewed publications. For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com. Investor Contact Frequently asked questions. When is SI-BONE presenting at the conference? SI-BONE will present on September 14, 2026, at 8:30 a.m. PT. How can investors listen to the conference? Investors can register to listen live or access the archived webcast on SI-BONE's website. What is SI-BONE known for? SI-BONE is a leader in developing solutions for clinical challenges related to compromised bone. How many procedures has SI-BONE supported? SI-BONE has supported over 150,000 procedures since its inception.

Yahoo Finance

Aug 3rd, 2026

SI-BONE reports 15% revenue growth to $56M, swings to positive adjusted EBITDA of $2.8M

SI-BONE reported second quarter 2026 worldwide revenue of $56.0 million, up 15.2% year-over-year. US revenue reached $53.2 million, growing 14.7%, driven by 14.9% procedure volume growth. International revenue was $2.8 million, up 25.9%. The medical device company achieved gross margin of 79.5% and positive adjusted EBITDA of $2.8 million, improving 178% year-over-year. Net loss was $4.1 million, a 33.6% improvement. Cash from operations turned positive at $0.8 million. The company's active US physician base grew 19% to 1,715. SI-BONE submitted a 510(k) application in June for its third breakthrough device targeting spine surgery needs. The Centers for Medicare & Medicaid Services finalised higher payment rates for complex spinal fusion procedures using iFuse Bedrock Granite, effective 1 October. SI-BONE raised its 2026 guidance following the results.

MarketBeat

Jul 28th, 2026

SiBone (NASDAQ:SIBN) shares gap up - still a Buy?

SiBone (NASDAQ:SIBN) shares gap up - still a Buy? July 28, 2026 Key points. * SiBone shares rose 4.8%, opening at $17.72 versus a prior close of $17.05 and last trading near $17.74. * Analyst sentiment remains favorable, with seven Buy ratings and one Sell rating producing a consensus "Moderate Buy" rating and a $23.57 target price. UBS initiated coverage with a Buy rating and a $24 target. * SiBone's latest quarterly results exceeded expectations, reporting an adjusted loss of $0.10 per share versus the $0.17 forecast and revenue of $52.59 million. However, the company remains unprofitable, while institutional investors own 98.11% of its shares and insiders have recently sold stock. * MarketBeat previews top five stocks to own in August. SiBone (NASDAQ:SIBN - Get Free Report) shares gapped up prior to trading on Tuesday. The stock had previously closed at $17.05, but opened at $17.72. SiBone shares last traded at $17.7410, with a volume of 252,650 shares. Wall Street Analyst weigh in. SIBN has been the subject of a number of recent research reports. UBS Group initiated coverage on shares of SiBone in a research note on Tuesday. They issued a "buy" rating and a $24.00 price objective for the company. Wall Street Zen lowered SiBone from a "buy" rating to a "hold" rating in a report on Saturday, April 18th. Truist Financial lifted their price target on SiBone from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, July 16th. TD Cowen decreased their price objective on SiBone from $22.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, May 12th. Finally, Weiss Ratings raised SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 21st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.57. SiBone trading up 4.8%. The firm's 50 day moving average is $15.97 and its 200 day moving average is $15.18. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The company has a market cap of $792.07 million, a PE ratio of -45.95 and a beta of 0.67. SiBone (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. The business had revenue of $52.59 million for the quarter, compared to analysts' expectations of $51.16 million. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. On average, equities analysts anticipate that SiBone will post -0.44 earnings per share for the current year. Insider buying and selling. In other SiBone news, SVP Michael A. Pisetsky sold 3,134 shares of the company's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $16.71, for a total value of $52,369.14. Following the transaction, the senior vice president directly owned 277,375 shares in the company, valued at $4,634,936.25. This represents a 1.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy E. Davis, Jr. sold 3,500 shares of the company's stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $14.14, for a total value of $49,490.00. Following the completion of the transaction, the director owned 65,722 shares in the company, valued at $929,309.08. This represents a 5.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,326 shares of company stock valued at $545,661 in the last ninety days. 4.00% of the stock is owned by insiders. Institutional trading of SiBone. Large investors have recently modified their holdings of the business. First Light Asset Management LLC increased its position in shares of SiBone by 162.4% in the fourth quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company's stock worth $99,249,000 after purchasing an additional 3,115,001 shares during the last quarter. Granahan Investment Management LLC grew its stake in SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock worth $21,965,000 after buying an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY grew its stake in SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company's stock worth $14,228,000 after buying an additional 598,300 shares in the last quarter. Cadian Capital Management LP increased its holdings in shares of SiBone by 96.8% in the 4th quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company's stock worth $23,094,000 after buying an additional 576,100 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of SiBone by 74.7% in the 3rd quarter. Wellington Management Group LLP now owns 853,266 shares of the company's stock worth $12,560,000 after buying an additional 364,897 shares during the last quarter. Institutional investors own 98.11% of the company's stock. SiBone company profile. Si-BONE, Inc is a commercial-stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain. FDA-cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider SiBone, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list. While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

SI-BONE

Territory Representative

About the job